Covestor Ltd Trims Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Covestor Ltd lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 91.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 357 shares of the medical equipment provider’s stock after selling 3,704 shares during the quarter. Covestor Ltd’s holdings in Lantheus were worth $39,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Atria Investments Inc bought a new position in Lantheus during the third quarter valued at approximately $330,000. Assetmark Inc. lifted its holdings in shares of Lantheus by 11.4% in the 3rd quarter. Assetmark Inc. now owns 62,802 shares of the medical equipment provider’s stock valued at $6,893,000 after buying an additional 6,442 shares during the period. AlphaCentric Advisors LLC acquired a new position in shares of Lantheus in the 3rd quarter valued at about $988,000. Moloney Securities Asset Management LLC purchased a new position in shares of Lantheus in the 3rd quarter valued at about $1,066,000. Finally, Citizens National Bank Trust Department increased its stake in shares of Lantheus by 2.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 12,798 shares of the medical equipment provider’s stock valued at $1,405,000 after purchasing an additional 298 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LNTH shares. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. JMP Securities dropped their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Down 5.0 %

Shares of Lantheus stock opened at $76.83 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market cap of $5.34 billion, a PE ratio of 12.78 and a beta of 0.51. The business’s fifty day moving average is $104.95 and its two-hundred day moving average is $96.24.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.